Kraj: Kanada
Język: angielski
Źródło: Health Canada
ALBUMIN (HUMAN)
GRIFOLS THERAPEUTICS LLC
B05AA01
ALBUMIN
5%
SOLUTION
ALBUMIN (HUMAN) 5%
INTRAVENOUS
50/250/500ML
Schedule D
BLOOD DERIVATIVES
Active ingredient group (AIG) number: 0131452001; AHFS:
APPROVED
2005-07-11
_ _ Page 1 of 17 PRODUCT MONOGRAPH ALBUMIN (HUMAN) 5% SOLUTION, USP Albumin (Human) 5%, USP Intravenous Solution, 5% Manufacturer’s Standard Plasma Substitute/Blood Derivative Manufactured by: Grifols Therapeutics Inc. 8368 U.S. 70 Bus. Hwy West Clayton, North Carolina 27520 U.S.A. Imported and Distributed by: Grifols Canada Ltd. 5060 Spectrum Way, Suite 405 Mississauga, Ontario L4W 5N5 Prepared for: Canadian Blood Services and/or Héma-Québec Submission Control No: 202697 Date of Approval: August 22, 2017 _ _ Page 2 of 17 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 DESCRIPTION....................................................................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................5 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ....................................................................................................6 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION ................................................................................8 OVERDOSAGE ..................................................................................................................9 ACTION AND CLINICAL PHARMACOLOGY ..............................................................9 STORAGE AND STABILITY ..........................................................................................10 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................10 PART II: SCIENTIFIC INFORMATION ....................... Przeczytaj cały dokument